Variables | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
HR (95% CI) | P-value | HR (95% CI) | P-value | |
Lung cancer | 3.55 (1.13–11.15) | 0.030 | 1.60 (0.30–8.63) | 0.586 |
Palliative setting | 4.83 (1.09–21.43) | 0.038 | 58.61 (0.26–13,356.90) | 0.142 |
Duration of neutropenia | 1.08 (1.03–1.15) | 0.003 | 1.27 (1.05–1.53) | 0.013 |
CRP | 1.04 (1.00–1.08) | 0.035 | 1.06 (1.00–1.11) | 0.021 |
MASCC risk index | 0.80 (0.68–0.95) | 0.010 | 0.80 (0.65–0.99) | 0.042 |
Combination therapy | 0.27 (0.09–0.85) | 0.025 | 0.85 (0.20–3.67) | 0.827 |
Types of β-lactams | ||||
Cefepime | 0.28 (0.10–0.81) | 0.019 | 0.64 (0.17–2.46) | 0.518 |
Ceftazidime | 2.05 (0.58–7.25) | 0.268 | ||
Piperacillin-tazobactam | 1.42 (0.40–5.02) | 0.589 | ||
Carbapenem | 5.95 (1.89–18.70) | 0.002 | 0.28 (0.01–50.00) | 0.631 |